Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis

Abstract

The incidence of renal flares and the long-term outcome in a group of 33 systemic lupus erythematosus (SLE) patients with diffuse proliferative glomerulonephritis (DPGN) treated with pulse steroids and a short course of pulse cyclophosphamide (CYC) are evaluated. Fifteen patients (45%) experienced a flare of renal disease at some time after the discontinuation of the immunosuppressive (IS) therapy; among these half (24%) were ‘early’ flares occurring shortly after the discontinuation of therapy, and the other half (21%) were ‘late’ flares occurring more than 2 y after the discontinuation of the treatment. Nine patients (27%) showed a poor renal outcome at the end of follow-up. On multiple regression analysis, a younger age and a high activity index (AI) on renal histology were found to be correlated with the occurrence of renal flares. Our results suggest that the combination of pulse steroids with a short course of pulse CYC (six to nine pulses) is effective in both controlling disease activity and in preventing the occurrence of renal flares in DPGN. However, short term IS therapy might not be sufficient to maintain disease control in younger patients with active lesions on renal histology. Such patients might be candidates to receive more prolonged IS treatment.

Keywords

pulse methylprednisolone pulse cyclophosphamide diffuse proliferative glomerulonephritis renal outcome renal flares

Get full access to this article

View all access options for this article.

References

Moroni G , Quaglini S , Maccario M , Banfi G , Ponticelli C. ‘ Nephritic flares’ are predictors of bad long-term renal outcome in lupus nephritis . Kidney Int 1996; 50: 2047-2053 .

Ponticelli C , Moroni G. Flares in lupus nephritis: incidence, impact on renal survival and management . Lupus 1998; 7: 635-638 .

Austin HA , Balow JE . Natural history and treatment of lupus nephritis . Semin Nephrol 1999; 19: 2-11 .

Doria A , Vitali C , Tincani A et al. International survey on the management of patients with SLE. III. The results of a questionnaire regarding renal involvement . Clin Exp Rheumatol 1996; 14(Suppl 16): 31-38 .

Bansal VK , Beto JA . Treatment of lupus nephritis: a meta-analysis of clinical trials . Am J Kidney Dis 1997; 29: 193-199 .

Austin HA III , Klippel JH , Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs . New Engl J Med 1986; 314: 614-619 .

Steinberg AD , Steinberg SC . Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only . Arthritis Rheum 1991; 34: 945-950 .

Boumpas DT , Austin HA III , Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet 1992; 340: 741-745 .

Gourley MF , Austin HA , Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial . Ann Intern Med 1996; 125: 549-557 .

10.

Boumpas DT , Austin HA III , Vaughan EM , Yarboro CH , Klippel JH , Balow JE . Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy . Ann Intern Med 1993; 119: 366-369 .

11.

Kinlen LJ . Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment . Am J Med 1985; 78(Suppl 1A): 44-49 .

12.

D'Cruz D , Cuadrado MJ , Mujic F et al. Immunosuppressive therapy in lupus nephritis . Clin Exp Rheumatol 1997; 15: 275-282 .

13.

Boumpas DT , Balow JE . Outcome criteria for lupus nephritis trials: a critical overview . Lupus 1998; 7: 622-629 .

14.

Vitali C , Bencivelli W , Isenberg DA , Smolen JS , Snaith ML , Sciuto M and the European Consensus Study Group for Disease Activity in SLE . Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score . Clin Exp Rheumatol 1992; 10: 541-547 .

15.

Austin HA III , Muenz LR , Joyce KM et al. Prognostic factors in lupus nephritis: contribution of renal histologic data . Am J Med 1983; 75: 382-391 .

16.

Sesso R , Monteiro M , Sato E , Kirsztajn G , Silva L , Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis . Lupus 1994; 3: 107-112 .

17.

Ciruelo E , de la Cruz J , Lopez I , Gomez-Reino JJ . Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide . Arthritis Rheum 1996; 39: 2028-2034 .

18.

Pablos JL , Gutierrez-Millet V , Gomez-Reino JJ . Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal . Scand J Rheumatol 1994; 23: 142-144 .

19.

Hoch S , Schur PH . Methylprednisolone pulse therapy for lupus nephritis: a follow-up study . Clin Exp Rheumatol 1984; 2: 313-320 .

20.

Liebling MR , McLaughlin K , Boonsue S , Kasdin J , Barnett EV . Monthly pulses of methylprednisolone in SLE nephritis . J Rheumatol 1982; 9: 543-548 .

21.

Valeri A , Radhakrishnan J , Estes D et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study . Clin Nephrol 1994; 42: 71-78 .

22.

Esdaile JM , Levinton C , Fegergreen W , Hayslett JP , Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature . Q J Med 1989; 72: 779-833 .

23.

de Glas-Vos JW , Krediet RT , Weening JJ , Arisz L. Treatment of proliferative lupus nephritis with methylprednisolone pulse therapy and oral azathioprine . Neth J Med 1995; 46: 4-14 .

24.

Dostal C , Tesar V , Rychlik I et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study . Lupus 1998; 7: 29-36 .

25.

Dooley MA , Cosio FG , Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations . J Am Soc Nephrol 1999; 10: 833-839 .